PPI-G4-M3 dendrimers
/ GeneaMed
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 21, 2020
Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL.
(PubMed, Toxicol Appl Pharmacol)
- "Cationic PPI-G4-M3 showed the highest anti-tumor activity but also higher toxicity than the neutral dendrimers and fludarabine. These first promising results warrant further studies in the optimization of dendrimers charge, dose, route and schedule of administration to combat CLL."
Journal • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • ATR
1 to 1
Of
1
Go to page
1